US-Based Emmes Acquires VaxTRIALS

Go back to Newsroom

US-Based Emmes Acquires VaxTRIALS

This strategic acquisition is part of Emmes’ broader objective to expand its global presence beyond its existing operations in North America, Europe, and Asia into the Latin American market. The move is expected to strengthen Emmes’ expertise in one of its core research focus areas: vaccines and infectious diseases.

US-based Clinical Research Organisation (CRO) Emmes has acquired VaxTRIALS, a specialised Clinical Research Organisation headquartered in Panama City.

Go back to Newsroom

Essex Management Appoints David Loose as Chief Executive Officer Appointment Reflects Commitment to Continuing Essex’s Strategic Vision ROCKVILLE, MD

Go back to Newsroom

Essex Management Appoints David Loose as Chief Executive Officer Appointment Reflects Commitment to Continuing Essex’s Strategic Vision ROCKVILLE, MD

Essex Management, an Emmes Group company and a leader in biomedical informatics and health information technology, is pleased to announce the appointment of David Loose as Chief Executive Officer (CEO), effective immediately. David succeeds Kevin Hurley, who has served as CEO since February 2019 and will transition to the role of Executive Advisor.

Download Go back to Newsroom

Emmes Group Earns ISO 27001:2022 Certification for Data Security

Go back to Newsroom

Emmes Group Earns ISO 27001:2022 Certification for Data Security

Emmes Group, a specialized, technology-enabled Contract Research Organization (CRO), has achieved ISO/IEC 27001:2022 certification after a rigorous audit. This data security certificate, widely regarded as the gold standard for Information Security Management Systems (ISMS), guarantees that Emmes Group and its subsidiary companies, Emmes and Veridix, adhere to the highest global standards for safeguarding sensitive information across its workforce, processes, and technology.

Download Go back to Newsroom
Subscribe to